MedTrace Logo

Rehabilitation of Critically Ill Patients With SARS-CoV-2 Variants in ICU With Limited Resources

NCT05450120 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2022-08-08

No results posted yet for this study

Summary

Acute rehabilitation in critically ill patients can improve post-intensive care unit (post-ICU) physical function. Scientific evidence has considered neuromuscular electrical stimulation (NMES) as a promising approach for the early rehabilitation of patients during and/or after ICU.

Neuromuscular electrostimulation can be an alternative form of muscle exercise that helps to gain strength in critically ill patients with COVID -19, due to the severe weakness that patients experience due to longer MV, analgesia and NMB duration. Thus, the general objective of evaluating the effects of an early rehabilitation protocol on the strength and functionality of patients affected by SARS-CoV-2 variants and specifically compare the effectiveness of NMES associated with the functional rehabilitation protocol(FR). Also, describe demographics, clinical status, ICU therapies, mortality estimates and Hospital outcomes, of every patients admitted in ICU during the observation periods.

Conditions

  • COVID-19 Acute Respiratory Distress Syndrome

Interventions

OTHER

Functional Rehabilitation

Functional rehabilitation protocol

OTHER

Neuromuscular Electrical Stimulation

Neuromuscular electrical stimulation protocol

Sponsors & Collaborators

  • Universidade Federal de Sao Carlos

    lead OTHER

Principal Investigators

  • Jacqueline Vianna, Phd · UFSCAR

  • Jamami, Phd · UFSCAR

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-01
Primary Completion
2020-10-01
Completion
2022-12-01

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05450120 on ClinicalTrials.gov